{"id":"chlorambucil-drug","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"20-40","effect":"Nausea and vomiting"},{"rate":"30-50","effect":"Anemia"},{"rate":"10-20","effect":"Infection"},{"rate":"1-5","effect":"Secondary malignancy"},{"rate":null,"effect":"Infertility"},{"rate":"5-10","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chlorambucil belongs to the nitrogen mustard class of alkylating agents. It forms covalent bonds with DNA bases, creating interstrand and intrastrand cross-links that disrupt DNA replication and transcription. This leads to apoptosis in rapidly dividing cells, particularly lymphoid malignancies.","oneSentence":"Chlorambucil is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:04.549Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Lymphomas (Hodgkin and non-Hodgkin)"},{"name":"Waldenström macroglobulinemia"}]},"trialDetails":[{"nctId":"NCT03462719","phase":"PHASE3","title":"A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-17","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":211},{"nctId":"NCT04075292","phase":"PHASE3","title":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-01-20","conditions":"Untreated Chronic Lymphocytic Leukemia","enrollment":155},{"nctId":"NCT01808599","phase":"PHASE2","title":"Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2013-12","conditions":"MALT Lymphoma","enrollment":112},{"nctId":"NCT02242942","phase":"PHASE3","title":"Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-12-31","conditions":"Lymphocytic Leukemia, Chronic","enrollment":445},{"nctId":"NCT02475681","phase":"PHASE3","title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2015-06-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":535},{"nctId":"NCT02612311","phase":"PHASE3","title":"Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2015-11-19","conditions":"Chronic Lymphocytic Leukemia","enrollment":603},{"nctId":"NCT01724346","phase":"PHASE3","title":"Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2013-12-03","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":269},{"nctId":"NCT06319456","phase":"PHASE3","title":"A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-04-07","conditions":"CLL/SLL","enrollment":344},{"nctId":"NCT05950997","phase":"NA","title":"A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-16","conditions":"Chronic Lymphocytic Leukemia","enrollment":89},{"nctId":"NCT04692740","phase":"PHASE2","title":"Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)","status":"UNKNOWN","sponsor":"Michele Reni","startDate":"2020-12-18","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT04578613","phase":"PHASE3","title":"ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL","status":"UNKNOWN","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2021-01-08","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":218},{"nctId":"NCT00558961","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients","status":"TERMINATED","sponsor":"Jewish General Hospital","startDate":"2005-10","conditions":"Chronic Lymphocytic Leukemia","enrollment":13},{"nctId":"NCT02915224","phase":"","title":"A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-11-23","conditions":"Chronic Lymphocytic Leukemia","enrollment":50},{"nctId":"NCT02336048","phase":"PHASE1","title":"A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2015-06-26","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":38},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02264574","phase":"PHASE3","title":"A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2014-10-06","conditions":"Chronic Lymphocytic Leukemia, Small-Cell Lymphoma","enrollment":229},{"nctId":"NCT01905943","phase":"PHASE3","title":"A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-04","conditions":"Chronic Lymphocytic Leukemia","enrollment":979},{"nctId":"NCT02100852","phase":"PHASE1","title":"TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2014-03-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":19},{"nctId":"NCT00875667","phase":"PHASE2","title":"A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)","status":"COMPLETED","sponsor":"Celgene","startDate":"2009-04-30","conditions":"Mantle Cell Lymphoma, Lymphoma, Mantle-Cell","enrollment":254},{"nctId":"NCT04059081","phase":"PHASE2","title":"A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment","status":"UNKNOWN","sponsor":"Deok-Hwan Yang","startDate":"2019-07-09","conditions":"Chronic Lymphocytic Leukemia","enrollment":31},{"nctId":"NCT00910910","phase":"PHASE3","title":"Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)","status":"COMPLETED","sponsor":"Celgene","startDate":"2009-10-13","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":450},{"nctId":"NCT00748189","phase":"PHASE3","title":"Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-12-22","conditions":"Leukaemia, Lymphocytic, Chronic","enrollment":447},{"nctId":"NCT00210353","phase":"PHASE3","title":"Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2003-01","conditions":"Lymphoma, Mucosa-Associated Lymphoid Tissue","enrollment":454},{"nctId":"NCT00262795","phase":"PHASE3","title":"Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2003-09","conditions":"Chronic Lymphocytic Leukemia","enrollment":206},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT01283386","phase":"PHASE4","title":"A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-04-27","conditions":"Lymphocytic Leukemia, Chronic","enrollment":26},{"nctId":"NCT01403246","phase":"PHASE1, PHASE2","title":"Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2011-11","conditions":"Chronic Lymphocytic Leukemia","enrollment":9},{"nctId":"NCT01980875","phase":"PHASE3","title":"Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-04-21","conditions":"Chronic Lymphocytic Leukemia","enrollment":57},{"nctId":"NCT01010061","phase":"PHASE3","title":"CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12-21","conditions":"Lymphocytic Leukemia, Chronic","enrollment":787},{"nctId":"NCT02053610","phase":"PHASE3","title":"CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12-31","conditions":"Lymphocytic Leukemia, Chronic","enrollment":787},{"nctId":"NCT01998880","phase":"PHASE3","title":"CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12-22","conditions":"Lymphocytic Leukemia, Chronic","enrollment":787},{"nctId":"NCT01722487","phase":"PHASE3","title":"Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2013-03","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":269},{"nctId":"NCT00738374","phase":"PHASE2","title":"A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-03","conditions":"Lymphocytic Leukemia, Chronic","enrollment":97},{"nctId":"NCT01868893","phase":"PHASE2","title":"An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-08","conditions":"Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT00046683","phase":"PHASE3","title":"Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2001-07","conditions":"B Cell Chronic Lymphocytic Leukemia","enrollment":284},{"nctId":"NCT00532129","phase":"PHASE2","title":"A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Lymphocytic Leukemia, Chronic","enrollment":100},{"nctId":"NCT00566332","phase":"PHASE3","title":"Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"French Study Group on Chronic Lymphoid Leukemia","startDate":"2001-06","conditions":"Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma","enrollment":414},{"nctId":"NCT01563055","phase":"PHASE2","title":"A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04","conditions":"Leukaemia, Lymphocytic, Chronic","enrollment":10},{"nctId":"NCT00250718","phase":"PHASE2","title":"Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2004-10","conditions":"Non-Hodgkin's Lymphoma, Cancer","enrollment":17},{"nctId":"NCT01056510","phase":"PHASE4","title":"A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-03","conditions":"Lymphocytic Leukemia, Chronic","enrollment":357},{"nctId":"NCT01808326","phase":"PHASE2","title":"A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04","conditions":"Leukaemia, Lymphoblastic","enrollment":5},{"nctId":"NCT00117598","phase":"PHASE3","title":"Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-05","conditions":"Lymphoma","enrollment":169},{"nctId":"NCT00004218","phase":"PHASE3","title":"Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Leukemia Research Fund","startDate":"1999-10","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00003421","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"1998-06","conditions":"Lymphoma","enrollment":800},{"nctId":"NCT00404833","phase":"PHASE3","title":"Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental","status":"COMPLETED","sponsor":"Hospital Authority, Hong Kong","startDate":"2003-01","conditions":"Glomerulonephritis, Membranous, Glomerulosclerosis, Focal","enrollment":16},{"nctId":"NCT00002905","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Centro di Riferimento Oncologico - Aviano","startDate":"1995-06","conditions":"Lymphoma","enrollment":20},{"nctId":"NCT00003617","phase":"PHASE3","title":"Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach","status":"UNKNOWN","sponsor":"Lymphoma Trials Office","startDate":"1995-03","conditions":"Gastric Cancer","enrollment":200},{"nctId":"NCT00006250","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Lymphoma Trials Office","startDate":"2000-05","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT00003639","phase":"PHASE3","title":"Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Scotland and Newcastle Lymphoma Group","startDate":"1993-11","conditions":"Lymphoma","enrollment":200},{"nctId":"NCT00028691","phase":"PHASE3","title":"Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma","status":"UNKNOWN","sponsor":"Commissie Voor Klinisch Toegepast Onderzoek","startDate":"2002-12","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00608374","phase":"PHASE3","title":"Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma","status":"COMPLETED","sponsor":"Taunton and Somerset Hospital","startDate":"2006-06","conditions":"Lymphoma","enrollment":400},{"nctId":"NCT01109264","phase":"PHASE2","title":"Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2010-03","conditions":"Chronic Lymphocytic Leukemia","enrollment":147},{"nctId":"NCT00025064","phase":"PHASE2","title":"Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2000-01","conditions":"Lymphoma","enrollment":260},{"nctId":"NCT00417014","phase":"NA","title":"Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"","conditions":"Lymphoma","enrollment":358},{"nctId":"NCT00416377","phase":"NA","title":"Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"","conditions":"Lymphoma","enrollment":353},{"nctId":"NCT01678430","phase":"PHASE3","title":"A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment","status":"UNKNOWN","sponsor":"University of Liverpool","startDate":"2011-12","conditions":"Chronic Lymphocytic Leukaemia","enrollment":670},{"nctId":"NCT01657955","phase":"PHASE3","title":"Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Shandong Lanjin Pharmaceuticals Co.,Ltd","startDate":"2011-01","conditions":"Chronic Lymphocytic Leukemia, Leukemia, Neoplasms","enrollment":96},{"nctId":"NCT00151736","phase":"PHASE2","title":"Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"Cephalon","startDate":"2004-09","conditions":"Chronic Lymphocytic Leukemia","enrollment":88},{"nctId":"NCT00285389","phase":"PHASE2","title":"Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2002-02","conditions":"Mantle Cell Lymphoma","enrollment":39},{"nctId":"NCT00017108","phase":"PHASE3","title":"Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-03","conditions":"Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"chlorambucil (drug)","genericName":"chlorambucil (drug)","companyName":"International Extranodal Lymphoma Study Group (IELSG)","companyId":"international-extranodal-lymphoma-study-group-ielsg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chlorambucil is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death. Used for Chronic lymphocytic leukemia (CLL), Lymphomas (Hodgkin and non-Hodgkin), Waldenström macroglobulinemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}